Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

Journal of Infection and Chemotherapy

Volumn 6, Issue 3, 2000, Pages 148-150

  Ikejima, H ^a   Yamamoto, H ^a   Ishida, K ^a   Kaku, M ^a   Shimada, J ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Grepafloxacin (GPFX); MIC; Mycoplasma pneumoniae

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; GREPAFLOXACIN; MACROLIDE; MINOCYCLINE; NEW DRUG; OFLOXACIN; QUINOLONE DERIVATIVE; ROXITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM; BACTERIUM ISOLATE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN;

EID: 0033783515     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560070013     Document Type: Article

References (9)

1. Long-term epidemiology of infections with Mycoplasma pneumoniae
2. Comparison of antibiotics in the treatment of Mycoplasmal pneumonia
3. New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy
4. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae
5. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics
6. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as PPLO
7. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae
8. Susceptibility of Mycoplasma pneumoniae to several new quinolines, tetracycline, and erythromycin
9. Susceptibility of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinoline, OPC 17116